Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5594
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers ; day:3 ; month:8 ; year:2018 ; pages:1-11
Oncogene ; (3.8.2018), 1-11
- Urheber
-
Wang, Edina
- Beteiligte Personen und Organisationen
-
Sorolla, Anabel
Cunningham, Paula T.
Bogdawa, Heique M.
Beck, Samuel
Golden, Emily
Dewhurst, Robert E.
Florez, Laura
Cruickshank, Mark N.
Hoffmann, Katrin
Hopkins, Richard M.
Kim, Jonghwa
Woo, Andrew J.
Watt, Paul M.
Blancafort, Pilar
SpringerLink (Online service)
- DOI
-
10.1038/s41388-018-0421-y
- URN
-
urn:nbn:de:101:1-2018100521485801153899
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Edina
- Sorolla, Anabel
- Cunningham, Paula T.
- Bogdawa, Heique M.
- Beck, Samuel
- Golden, Emily
- Dewhurst, Robert E.
- Florez, Laura
- Cruickshank, Mark N.
- Hoffmann, Katrin
- Hopkins, Richard M.
- Kim, Jonghwa
- Woo, Andrew J.
- Watt, Paul M.
- Blancafort, Pilar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2
Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism
The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase
Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Cell-penetrating peptides as potent vectors for the delivery of nucleic acids and therapeutically active molecules
Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2
Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism
The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase
Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Cell-penetrating peptides as potent vectors for the delivery of nucleic acids and therapeutically active molecules
Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2
Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism
The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase
Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer